Morning and nocturnal serum melatonin rhythm levels in patients with major depressive disorder: an analytical cross-sectional study

Khaleghipour, Shahnaz; Masjedi, Milad; Ahade, H; Enayate, M; Pasha, Gholamreza; Nadery, Farah; Ahmadzade, Gholamhossein

doi:10.1590/s1516-31802012000300006

Cited by 42 publications

(23 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The serum MLT values below 38.9 pg/ml sampled at 7 a.m. were furthermore identi ed as values with higher risk for OSCC incidence, with a speci city of 75% and sensitivity of 76.6%. Unfortunately, the authors did not explain or comment on the high MLT levels obtained in the healthy control group, which are inconsistent with other studies on MLT levels with healthy subjects older than fty [31,32] and rather correlate with the nocturnal levels of MLT in healthy subjects [40,[43][44][45].…”

Section: Discussioncontrasting

confidence: 61%

Salivary Melatonin in Oral Squamous Cell Carcinoma Patients: A Cross-sectional Study

Salarić

Karmelić

Lovrić

et al. 2020

Preprint

View full text Add to dashboard Cite

BACKGROUND: Around 55% of oral squamous cell carcinoma (OSCC) patients are diagnosed in the advanced stage. Poor sleep quality has been associated as a potential risk factor for several malignancies, including head and neck cancers. Melatonin’s role in circadian rhythm is well documented, as are its’ anti-oxidant, oncostatic and anti-inflammatory properties. The purpose of this study is to determine salivary melatonin (MLT) levels in OSCC patients, compare the salivary MLT levels with those in healthy individuals and compare the salivary and serum levels in OSCC patients. Furthermore, the aim is to evaluate sleep quality and to investigate the potential relationship between sleep quality and salivary MLT levels in OSCC patients. METHODS: Unstimulated and stimulated saliva were sampled from patients with T1N0M0 and T2N0M0 OSCC (N=34) and 33 sex and age matched healthy subjects. Serum samples were taken from 11 OSCC patients. Detailed medical history was taken before sampling and sleep quality measured using Pittsburgh Sleep Quality Index (PSQI) questionnaire. RESULTS: Melatonin levels in UWS and SWS were significantly higher in the OSCC group. Sleep quality was significantly lower in patients with OSCC (U=249.50; P = 0.0001). ROC analysis was found to be significant (P <0.001) in evaluating the MLT concentration limit in diagnosing OSCC. CONCLUSIONS: The expected relationship between sleep quality and salivary MLT levels in OSCC patients was not observed. Salivary melatonin could present a potential OSCC biomarker. However, larger prospective studies should validate the clinical utility of MLT as an OSCC biomarker.

show abstract

Section: Discussioncontrasting

confidence: 61%

Salivary Melatonin in Oral Squamous Cell Carcinoma Patients: A Cross-sectional Study

Salarić

Karmelić

Lovrić

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…High values of endogenous blood melatonin peaks in critically ill patients could have contradictory meanings, since in septic patients, higher endogenous melatonin values were reported positively correlated with mortality if measured at sepsis diagnosis, whilst disruption of circadian cycle was associated with septic state . Since the nocturnal melatonin blood levels in healthy subjects could be assumed to be 67 ± 16 pg/mL, the levels found in these ICU patients were below the nocturnal physiological levels in 71% of the cases.…”

Section: Discussionmentioning

confidence: 98%

Different routes and formulations of melatonin in critically ill patients. A pharmacokinetic randomized study

Mistraletti

Paroni

Umbrello

et al. 2019

Clinical Endocrinology

View full text Add to dashboard Cite

have contributed equally to the present paper.Precis: Melatonin encapsulated in solid lipid nanoparticles enterally administered in critically ill patients has useful pharmacokinetics; transdermal microemulsion has concentration-time profile more similar to endogenous one. AbstractBackground and objectives: Critically ill patients present reduced endogenous melatonin blood levels, and they might benefit from its exogenous supplementation. The aim of this research was to evaluate the feasibility of different routes of administration and drug formulations of melatonin. The efficiency of absorption was assessed as well as the adequacy in achieving and maintaining the physiological nocturnal blood peak.Methods: Twenty-one high-risk critically ill patients were randomly assigned to receive melatonin either: (a) per os, as a standard tablet (ST-OS), (b) per os, as a suspension in solid lipid nanoparticles (SLN-OS) or c) transdermal (TD), by applying a jellified melatonin microemulsion (μE) on the skin (μE-TD). SLN-OS and μE-TD were lipidbased colloidal systems. The endogenous melatonin blood values were observed for 24 hours; subsequently, melatonin 3 mg was administered and pharmacokinetics was studied for 24 hours further. Results:In both groups that received ST-OS and SLN-OS, the median time-topeak blood concentration was 0.5 hours; however, the area under the curve (AUC) after administration of SLN-OS was significantly higher than after ST-OS (157386 [65732-193653] vs 44441 [22319-90705] pg/mL*hours, P = 0.048). μE-TD presented a delayed time-to-peak blood concentration (4 hours), a lower bioavailability (AUC: 3142 [1344-14573] pg/mL*hours) and reached pharmacological peak concentration (388 [132-1583] pg/mL).Conclusions: SLN-melatonin enterally administered offers favourable pharmacokinetics in critically ill patients, with higher bioavailability with respect to the standard formulation; μE-TD provided effective pharmacological blood levels, with a time-concentration profile more similar to the physiological melatonin pattern. K E Y W O R D Scritically ill patients, lipid nanovector encapsulation, melatonin, microemulsion, transdermal absorption

show abstract

“…A cross-sectional study in 2012 further supported the low melatonin hypothesis [84] by showing that nocturnal melatonin levels in patients with depression are signifi cantly lower than in controls. Other than the concentration changes, a change in the biological rhythm of melatonin is also an important factor.…”

Section: The Circadian Rhythm Disorder Hypothesis and New Targets Formentioning

confidence: 91%

New hypothesis and treatment targets of depression: an integrated view of key findings

2015

View full text Add to dashboard Cite

Major depressive disorder (MDD) is a common and devastating psychiatric disorder characterized by persistent low mood, cognitive disorder, and impaired social function. Despite its complex mechanisms, increasing evidence has identified the involvement of neurotrophic factors, inflammatory cytokines, the hypothalamuspituitary-adrenal axis, and glutamate receptors in the pathophysiology of this illness. The present review synthesizes recent research achievements to defi ne the network between different hypotheses of MDD and to understand which part is most pivotal for its pathogenesis. By integrating MDD-related signal pathways, we highlight brain-derived neurotrophic factor (BDNF) dysfunction and increased apoptosis as the fi nal common cascades, and new therapeutic strategies aiming to enhance BDNF function have been shown to exert a rapid and effective antidepressant action.

show abstract

Morning and nocturnal serum melatonin rhythm levels in patients with major depressive disorder: an analytical cross-sectional study

Cited by 42 publications

References 24 publications

Salivary Melatonin in Oral Squamous Cell Carcinoma Patients: A Cross-sectional Study

Salivary Melatonin in Oral Squamous Cell Carcinoma Patients: A Cross-sectional Study

Different routes and formulations of melatonin in critically ill patients. A pharmacokinetic randomized study

New hypothesis and treatment targets of depression: an integrated view of key findings

Contact Info

Product

Resources

About